approval

August 29, 2017August 30, 2017

Merck’s Mavenclad, an Oral Therapy for Relapsing MS, Approved in European Union

News

The European Commission has approved Merck KGaA’s Mavenclad (cladribine tablets) to treat highly active relapsing forms of multiple sclerosis (MS). The Aug. 25 decision in Brussels marks the first approval of a ... Read more

August 22, 2017August 23, 2017

Mavenclad Improves Relapsing MS Patients’ Quality of Life, Independent U.K. Study Finds

News

Merck’s Mavenclad tablets significantly improve quality of life among relapsing multiple sclerosis patients while reducing the number of relapses, according to new analyses of previously unpublished data from clinical ... Read more

July 18, 2017July 19, 2017

Australian Authorities Approve Ocrevus Following U.S. Endorsement of Breakthrough MS Therapy

News

Australia has become the first country to approve Genentech’s Ocrevus for relapsing and primary progressive multiple sclerosis treatment since the therapy’s initial approval by the U.S. Food and Drug ... Read more

June 27, 2017June 29, 2017

Cladribine Tablets Are Only a Step Away from European Union Approval for Relapsing Multiple Sclerosis

News

Merck’s cladribine tablets are now just one step away from obtaining European Union approval as a relapsing multiple sclerosis treatment. The European Medicines Agency’s Committee for Medicinal Products for Human ... Read more

May 25, 2017May 25, 2017

Fampyra Granted Standard Approval in Europe as Trial Results Support Effectiveness

News

Fampyra (prolonged-release fampridine tablets) — sold in the U.S. as Ampyra (dalfampridine) — has now been granted standard marketing authorization in Europe. The approval was based on the results ... Read more

April 6, 2017April 6, 2017

‘Adequate and Rapid Delivery’ of Ocrevus Expected, Says Genentech Director in Interview

News

Ocrevus (ocrelizumab), now approved for both relapsing and primary progressive multiple sclerosis (MS), is expected to become available in the coming week. While patients and neurologists are waiting, Multiple Sclerosis ... Read more

April 5, 2017April 5, 2017

UCSF Neurologist Played Key Role in MS Research Turning to B-Cells, Essential Step to Ocrevus

News

Dr. Stephen Hauser, chair of the neurology department at the University of California San Francisco, was instrumental in the early research and later clinical trials that ultimately led to Ocrevus (ocrelizumab), ... Read more

April 4, 2017April 4, 2017

Transcript of Interview with Dr. Robert Lisak, a Neurologist and MS Expert, About Ocrevus

News

Here is a transcript of the Multiple Sclerosis News Today interview about Ocrevus (ocrelizumab) with Dr. Robert Lisak of the Consortium of Multiple Sclerosis Centers (CMSC). Lisak, a professor ... Read more

April 4, 2017April 4, 2017

Ocrevus Holds Promise, But Needs to Prove Itself in ‘Long Term,’ Says Dr. Robert Lisak with CMSC

News

Interest in  Ocrevus (ocrelizumab), the first FDA-approved treatment for both relapsing and primary progressive multiple sclerosis, is running high among patients and the organization representing them — as, arguably, are expectations ... Read more

March 30, 2017March 30, 2017

Hope, But No Cheers Yet, Voiced by MS Groups in Europe and Canada Waiting on Own Ocrevus Decision

News

American patient groups and neurologists have clearly been giving Ocrevus (ocrelizumab) plenty of attention since news of its approval landed, as a sweep of U.S. reaction to the FDA’s decision showed. ... Read more

March 29, 2017March 29, 2017

Excitement to Cautious Optimism — Reactions to Approval of Ocrevus

News

The historic approval of Ocrevus (ocrelizumab), the first-ever treatment for primary progressive multiple sclerosis (MS), set off ripples in the relatively calm waters of MS news reporting. The drug, which ... Read more

March 16, 2017March 16, 2017

After Long Wait, Zinbryta Gains Approval in Areas of the UK

Columns, What's Important Now -- An MS Column by Ian Franks

News that daclizumab, brand name Zinbryta, has been given the go-ahead to be available through the U.K.’s National Health Service (NHS) for treating relapsing MS, at least in part of ... Read more

October 4, 2016October 12, 2016

NICE Planning to Reject MS Treatment, Zinbryta, in England and Wales

News

The National Institute for Health and Care Excellence (NICE), the health authority for England and Wales, has decided not to recommend Zinbryta (daclizumab) be made available to multiple sclerosis (MS) patients through the country’s ... Read more

May 31, 2016May 31, 2016

Multiple Sclerosis treatment Zinbryta (Daclizumab) Approved by FDA

News

Zinbryta (daclizumab) was approved May 27 for the treatment of adults with relapsing multiple sclerosis (MS). The U.S. Food and Drug Administration (FDA) cleared Biogen’s new long-acting injection as ... Read more